Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $67.6 million.

  • Xeris Biopharma Holdings' Operating Expenses rose 72.66% to $67.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.3 million, marking a year-over-year increase of 1023.88%. This contributed to the annual value of $236.7 million for FY2024, which is 1384.74% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Operating Expenses is $67.6 million, which was up 72.66% from $67.1 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Operating Expenses registered a high of $69.7 million during Q4 2021, and its lowest value of $24.9 million during Q1 2021.
  • Its 5-year average for Operating Expenses is $52.6 million, with a median of $54.0 million in 2023.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Operating Expenses soared by 11488.47% in 2021 and then plummeted by 3068.29% in 2022.
  • Xeris Biopharma Holdings' Operating Expenses (Quarter) stood at $69.7 million in 2021, then tumbled by 30.68% to $48.3 million in 2022, then increased by 12.25% to $54.2 million in 2023, then increased by 7.72% to $58.4 million in 2024, then grew by 15.8% to $67.6 million in 2025.
  • Its Operating Expenses was $67.6 million in Q3 2025, compared to $67.1 million in Q2 2025 and $63.2 million in Q1 2025.